We serve Chemical Name:5-[4-(trifluoromethyl)phenyl]-1,2,4-oxadiazole-3-carboxylic acid CAS:652979-81-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
![5-[4-(trifluoromethyl)phenyl]-1,2,4-oxadiazole-3-carboxylic acid](https://a.dearchem.com/CAS2/652979-81-2.png)
Chemical Name:5-[4-(trifluoromethyl)phenyl]-1,2,4-oxadiazole-3-carboxylic acid
CAS.NO:652979-81-2
Synonyms:5-[4-(trifluoromethyl)phenyl]-1,2,4-oxadiazole-3-carboxylic acid
Molecular Formula:C10H5F3N2O3
Molecular Weight:258.15400
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:76.22000
Exact Mass:258.02500
LogP:2.45360
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 5-[4-(trifluoromethyl)phenyl]-1,2,4-oxadiazole-3-carboxylic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,5-[4-(trifluoromethyl)phenyl]-1,2,4-oxadiazole-3-carboxylic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,5-[4-(trifluoromethyl)phenyl]-1,2,4-oxadiazole-3-carboxylic acid Use and application,5-[4-(trifluoromethyl)phenyl]-1,2,4-oxadiazole-3-carboxylic acid technical grade,usp/ep/jp grade.
Related News: (For more on Stevanato, see The Covid Vaccine Will Require Billions Of Tiny Glass Vials—And This Italian Billionaire Family Is Making Them.) 2,2-difluorocyclohexan-1-amine manufacturers CHMP on Friday also announced that Roche pulled its Tecentriq application in triple-negative breast cancer after it noted that the EMA said the results from a late-stage trial do not favor the drug’s benefit-risk calculation in this indication. 2-(3-fluorophenyl)butanedioic acid suppliers Injectable drug devices such as pens and cartridges accounted for 45% of the company’s sales last year, followed by insulin products with 16%. 6-chloro-4-oxo-1H-1,5-naphthyridine-3-carboxylic acid vendor & factory The CHMP concluded that the benefits of Zynteglo continue to outweigh its risks. As for all medicines, the EMA will monitor any new data on its safety and update advice for patients and healthcare professionals when necessary.,CHMP on Friday also announced that Roche pulled its Tecentriq application in triple-negative breast cancer after it noted that the EMA said the results from a late-stage trial do not favor the drug’s benefit-risk calculation in this indication.
